AMRN Earnings Date: Feb 24, 2027 (Estimated) — Amarin Corporation plc
NASDAQ · Healthcare · Drug Manufacturers - General
Updated
When is AMRN's next earnings date?
Amarin Corporation plc (AMRN) is expected to report Q4 2026 earnings on Wednesday, February 24, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $47.0M.
How did AMRN do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), Amarin Corporation plc posted EPS of $0.08 versus the -$0.10 estimate, a beat of 182.3%. Revenue was $36.9M against a $43.8M estimate. The stock's 1-day post-earnings move was +6.7%.
How much does AMRN stock move after earnings?
AMRN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.5% (up or down) in the day after earnings.
About Amarin Corporation plc
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
🤖 AI Earnings Analysis
Amarin’s reported positive net income is a welcome catalyst, yet the cardiovascular-drug maker delivered just $37M revenue, down from $50M a year ago and $7M below estimates; $0.08 EPS beat masks weak demand and an operating loss.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | -0.10 | 0.08 | +182.32% | $36.9M | ✅ Beat | +6.65% | — | — |
| 2026-07-29 | Q2 2026 | -0.12 | 0.00 | +100.00% | $42.2M | ✅ Beat | +1.51% | +3.23% | +3.05% |
| 2026-04-29 | Q1 2026 | -0.41 | 0.00 | +100.00% | $45.1M | ✅ Beat | +2.36% | +3.87% | +3.22% |
| 2026-02-25 | Q4 2025 | -0.56 | 0.01 | +101.79% | $49.2M | ✅ Beat | -9.47% | -7.54% | -5.41% |
| 2025-10-29 | Q3 2025 | -0.03 | 0.19 | +733.33% | $49.7M | ✅ Beat | -11.25% | -19.75% | -14.78% |
| 2025-07-30 | Q2 2025 | -0.61 | 0.04 | +106.56% | $72.7M | ✅ Beat | +2.18% | +3.28% | +5.60% |
| 2025-03-12 | Q4 2024 | -0.03 | -0.02 | +33.33% | $62.3M | ✅ Beat | -14.94% | -8.01% | -2.57% |
| 2024-10-30 | Q3 2024 | -0.05 | -0.05 | +0.00% | $42.3M | ➖ Inline | -3.74% | -1.58% | -15.86% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $39.5M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 93.3% | $36.9M | -24.0% | $41.0M | $46.6M | $48.6M | $46.5M |
| Licensing And Royalty | 6.7% | $2.7M | +139.2% | $982K | $26.1M | $1.1M | $2.7M |
By region
Q3 FY26 · $32.2M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 88.5% | $28.5M | -30.2% | $36.5M | $40.9M | $41.1M | $35.6M |
| Europe | 11.5% | $3.7M | -9.3% | $6.6M | $4.1M | $2.3M | $4.9M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.